Evidence map›Paper›PMID 41057234›Full record

GuidelineGut2026

Asian Pacific Association of Gastroenterology task force recommendations on surveillance for

Wai Keung Leung, Tiing Leong Ang, Shailja Shah, Ka Shing Cheung, Yunhao Li, Noriya Uedo, Wen-Qing Li, Khay-Guan Yeoh, Ratha-Korn Vilaichone, Thomas Kl Lui and 10 more

Abstract readSystematic ReviewPractice Guideline
In one paragraph

Guideline in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Collaborating to strengthen evidence-based care.Singapore medical journal · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Wai Keung LeungDepartment of Medicine, University of Hong Kong, Hong Kong, China waikleung@hku.hk.ORCID 0000-0002-5993-1059
Tiing Leong AngDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Shailja ShahDivision of Gastroenterology and Hepatology, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-2049-9959
Ka Shing CheungDepartment of Medicine, University of Hong Kong, Hong Kong, China.ORCID 0000-0002-4838-378X
Yunhao LiDepartment of Medicine, University of Hong Kong, Hong Kong, China.
Noriya UedoDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.ORCID 0000-0002-3029-9272
Wen-Qing LiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Peking University Cancer Hospital and Institute, Beijing, China.ORCID 0000-0002-8336-5552
Khay-Guan YeohDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.ORCID 0000-0002-7802-4606
Ratha-Korn VilaichoneCenter of Excellence in Digestive Diseases, Gastroenterology Unit, Department of Medicine and Thailand Science Research and Innovation Fundamental Fund 2025, Thammasat University, Bangkok, Thailand.
Thomas Kl LuiDepartment of Medicine, University of Hong Kong, Hong Kong, China.
Duc Trong QuachDepartment of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.ORCID 0000-0003-0141-921X
Lai Mun WangDepartment of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Il Ju ChoiCenter for Gastric Cancer, National Cancer Center Hospital, Goyang-si, Korea (the Republic of).ORCID 0000-0002-8339-9824
Hidekazu SuzukiDepartment of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Hwoon-Yong JungDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (the Republic of).ORCID 0000-0003-1281-5859
Hang Viet DaoEndoscopy Center, Hanoi Medical University Hospital, Hanoi, Vietnam.
Kaichun WuXijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Alex BoussioutasSchool of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Mario Dinis-RibeiroPorto Comprehensive Cancer Center & RISE @ CI-IPO, University of Porto, Porto, Portugal.
Yi-Chia LeeDepartments of Internal Medicine and Medical Research, National Taipei University Hospital, Taipei, Taiwan.ORCID 0000-0002-8160-1216

Funding

CSRD VA IK2 CX002027
6 · The paper itself

Abstract

backgroundThe burden of gastric cancer remains substantial in Asia. Gastric premalignant conditions, including chronic atrophic gastritis, intestinal metaplasia and dysplasia, are important intermediate stages in the gastric carcinogenesis cascade. The sojourn time allows endoscopic surveillance to have a pivotal role in early detection and timely intervention.

objectiveThis task force was commissioned by the Asian Pacific Association of Gastroenterology to formulate recommendations for the surveillance and management of

designA systematic literature review was conducted across multiple databases, including PubMed, Cochrane Library and Embase, focusing on studies related to gastric premalignant conditions and their surveillance, particularly from Asia. The evidence quality and strength of recommendations were appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

resultsThese recommendations address four key aspects of gastric premalignant condition surveillance: (1) epidemiology and risk factors; (2) endoscopic and histopathological diagnosis; (3) risk stratification and endoscopic surveillance strategies; and (4) management strategies. 28 statements were made after multiple rounds of voting by experts. The statements offer a comprehensive, evidence based framework designed to assist clinicians in the Asia Pacific region on the early detection and management of gastric premalignant conditions.

conclusionThese statements aim to provide a structured, evidence based surveillance framework for clinical practice in the Asia Pacific region, while also identifying priority areas for future research.

Indexed as

Helicobacter InfectionsHelicobacter pyloriPrecancerous ConditionsStomach NeoplasmsAsiaEarly Detection of CancerGastritis, AtrophicGastroscopyHumansMetaplasiaPopulation SurveillanceRisk FactorsDYSPLASIAENDOSCOPYGASTRIC METAPLASIAHELICOBACTER PYLORIPRE-MALIGNANCY - GI TRACT

Identifiers

PMID41057234
PMCPMC13018803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.